<DOC>
	<DOCNO>NCT01887626</DOCNO>
	<brief_summary>Study investigate uptake Ticagrelor body differs depend method administration .</brief_summary>
	<brief_title>Study Investigate Uptake Ticagrelor Into Body Differs Depending Method Administration .</brief_title>
	<detailed_description>Study evaluate bioavailability crush ticagrelor tablet administer orally nasogastric tube compare whole ticagrelor tablet give orally</detailed_description>
	<mesh_term>Adenosine</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Healthy male female volunteer age 18 50 year ( inclusive ) suitable vein cannulation repeat venepuncture Have body mass index 18 30 kg/m2 ( inclusive ) weigh least 50 kg ( 110 pound [ lbs ] ) 100 kg ( 220 lb ) . Provision sign date , write informed consent prior study specific procedure History clinically significant disease disorder , opinion Investigator , may either put volunteer risk participation study , influence result volunteer 's ability participate study History haemophilia , von Willebrand 's disease , lupus anticoagulant diseases/syndromes either alter increase propensity bleed A personal history vascular abnormality include aneurysm ; personal history severe haemorrhage , haematemesis , melena , haemoptysis , severe epistaxis , severe thrombocytopenia , intracranial haemorrhage ; rectal bleeding within 3 month prior screeening visit ; history suggestive peptic ulcer disease History frequent and/or significant nose bleed clinically significant non traumatic bleed , bruise/haematoma clinically significant bleeding risk , judge Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Phase 1 , pharmacokinetic , safety , Ticagrelor</keyword>
</DOC>